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Abstract
The aim of the study: to establish the cytoprotective ability of the application of Phenovine to mitogen-activated Jurkat cells’ modeling systems. 
Experiments were conducted on intact and PHA-stimulated Jurkat cells and in conditions of coincubation of intact and PHA-stimulated cells. Cytopro-
tectiv activity of Phenovine was established according to coefficients of viability of the cells and apoptosis intensity, calculated on the basis of the data 
from the MTT test. Based on the analysis of experimental data, it was concluded that the viability of Jurkat cells decreases (apoptosis intensity increases), 
while the rising ratio of activated and nonactivated cells in the incubation medium ([Jurkat]PHA/[Jurkat]intact). Therefore, Phenovin increases viability of 
PHA-stimulated Jurkat cells and prevents their apoptosis.
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Цитопротекторная активность феновина в митоген-активированных клетках Jurkat
Целью работы явилось исследование цитопротекторной активности феновина на митоген-активированных клетках Jurkat. Эксперименты 
проводились на интактных, PHA-стимулированных клетках Jurkat и в условиях совместной инкубации интактных и стимулированных клеток. 
Цитопротекторная активность феновина определялась по значению коэффициентов жизнеспособности клеток и интенсивности их апоптоза, 
которые рассчитывались из данных МТТ теста. На основании анализа результатов исследования сделано заключеиие, что жизнеспособность 
клеток Jurkat уменьшается, интенсивность апоптоза увеличивается, с увеличением соотношения PHA-стимулированных и не стимулированных 
клеток Jurkat в среде инкубации ([Jurkat]PHA/[Jurkat]интактные). Феновин увеличивает жизнеспособность PHA-стимулированных клеток Jurkat и 
предотвращает апоптоз.
Ключевые слова: феновин, митоген-активированные клетки Jurkat.
Introduction
Presently, much interest is focused on the autoimmune 
mechanism of atherosclerosis. It is known that infiltration of 
atherosclerotic plaques which is activated by T lymphocytes, 
occurs at an early stage and cytokines produced by those lym-
phocytes are actively involved in the inflammatory process 
[3, 6, 7, 8, 12]. Balance between pro- and anti-inflammatory 
cytokines may play crucial role in the progression of athero-
sclerosis. Pro-inflammatory cytokines are, hence, considered 
to bepro-atherogenic, anti-inflammatory-anti-atherogenic 
cytokines; and reduced production of anti-inflammatory cy-
tokines results in impaired clearance of apoptotic cell debris. 
It also should be mentioned that the over abundance of reac-
tive oxygen species (ROS) may induce apoptosis or necrosis 
in many cell types, which can cause tissue injury [1]. Apop-
tosis in activated T lymphocytes occurs at the same time as 
the over abundance of ROS and activation of MAP (mitogen-
activated protein) kinases; apoptotic microparticles accumu-
late in the lipid core of atherosclerotic plaques, as a result of 
reduced capacities to clear of apoptotic cells with foam mac-
rophages in an oxidant-rich environment [2].
The intensively proliferated Jurkat leukemic T cell line 
(human leukemic cell culture) is widely used in scientific 
and therapeutic research, as the human T lymphocyte pat-
tern [4, 5, 9, 13]. Jurkat line has been extensively studied as 
a model system for understanding the conditions involving 
T cell activation. The latter is commonly determined by IL-2 
secretion, which promotes T cell proliferation. The Jurkat 
T cell line, stimulated by phytohemaglutinine or Con A, is 
capable to produce 100 to 300 times as much IL-2 as lectin-
stimulated normal human peripheral blood lymphocytes. 
The Jurkat cell derived from IL-2 has the capability to induce 
proliferation of antigen-stimulated human effector cells in 
vitro. Therefore, the Jurkat cell model system is a valuable 
reagent for researchers interested in proliferation T clonal 
human lymphocytes of various antigen and effector specifi- 
city, and in particular, the effect of potentially anti-athero-
genic medications on cytokines and atherosclerosis-associ-
ated auto-antigenes such as oxidized LDL, Heat Shock pro-
tein, cardiolipine, and b-2-glycoproteine.
The autoimmune concept of atherosclerosis pathogenesis 
has been followed by a novel and promising strategy of athe- 
rosclerosis treatment and prevention, which occurs in the 
suppression of proatherogenic immune factors and the ac-
tivation of atheroprotective immune factors. Consequently, 
the preparations capable of stabilizing immune cells may 
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only be effective for the treatment and prevention of athero-
sclerosis.
An extensive volume of basic clinical and experimental 
research proves the beneficial effects of the antioxidant, im-
munomodulatory therapy of atherosclerosis. In recent years 
in modern medicine great attention has been paid to natural 
antioxidant compounds taken from vegetables. The protective 
effect of poliphenols in cardiovascular diseases is due to the 
antioxidant and antiradical properties of these compounds 
[4], their ability to act as chelates for metals with alternating 
valency, to have an effect on the activity of the cellular deto- 
xing system (superoxide dismutase (SOD), catalase, glutathi-
one peroxidase), and to inhibit ROS-generating enzymes (xan-
thine oxidase, NADPH-oxidase). Protective effect of red vine 
poliphenol, rezveratrol against oxLDL toxicity in endothelial 
cells is a well known phenomenon [11]. Though many aspects 
of phenol activity are still to be specified and elucidated. The 
application of Phenovin (registration¹ Р-000268, “Pharmi-
pecs” Ltd for i/p “Irakli Chkhikvishvili – ITA”), synthesized in 
Georgia from bioactive phenol compounds (flavonoids, phe-
nilpropanoids, stable phytoalexin from grape peel reserves?), 
is characterized by antioxidant, hypolipidemic, thrombolitic, 
and fibrinolitic properties.
The aim of the study: to establish the cytoprotective abili-
ty of the application of Phenovine on mitogen-activated Jur-
kat cells’ modeling systems.
Material and Methods
Cell culture: research was conducted on human leuke-
mic mature T cells (Jurkat cells) (DSMZ-Deutshe Sammu-
lung von Mikroorganismen und Zellkulturen (Germany). 
Cells were proliferated in the bioactive medium RPMI 1640 
(GIBSO), inactivated embrionic bovine serum (Sigma), 
L-glutamine (4mM), penicillin (100un/ml) and streptomy-
cin (100un/ml) contained in a medium at 370C T and 5% 
CO2 moisture. Experiments were carried out on cell at 0.3 
– 0,6 x 106 concentration in 1ml of medium. The following 
series of experiments were implemented:
1) Jurkat cells were pre-stimulated through incubation 
with 50, ug/ml PHA at 370 for 5 min;
2) PHA-prestimulated Jurkat cells cultured for 24 hours 
alone;
3) PHA-prestimulated Jurkat cells cultured for 24 hours 
mixed with non-stimulated Jurkat cells;
4) PHA-prestimulated Jurkat cells cultured for 24 hours 
mixed with non-stimulated Jurkat cells and Phenovine 
(LTD Irakli Chkikvishvili) in a dose of 0.2 μg/100 mi-
crolitre suspensions.
Modelling of Activation-induced cell death
Jurkat cells pre-stimulated with phytohaemagglutinin 
(PHA) induced the death of non-activated Jurkat cells. Time-
course analysis revealed that PHA-stimulated Jurkat cells 
quickly release a toxic molecule in the medium following a 
biphasic pattern, with maximal cytotoxic activities [10]. This 
data indicates the activation-induced cell death (AICD) in 
Jurkat cells.
The Jurkat cells (4 x 105 cells/ml) were pre-stimulated 
through incubation with 50, ug/ml PHA at 370 for 5 min. 
PHA was then removed by brief centrifugation in cells that 
had been washed three times with RPMI-1640, re-suspen-
ded in a complete medium, seeded in flat-bottom 96-well 
plates (25000 cells/well) and cultured for 24 hours alone or 
mixed with different concentration of non-stimulated Jurkat 
cells and Phenovine. We tested the toxicity of non-activated 
Jurkat cells with the MTT method.
The assessment MTT test of cells proliferation activity 
(viability)
We incubated cell suspended (2 x 106 cell/ml) in a growth 
medium (PRMI-1640 + 10% calf embryonic serum (sigma) 
+ 1% penicillin+streptomycin) (together with hydrogen pe-
roxide and antioxidant preparations) for 37°C in 5% CO2 at-
mosphere. After this, the incubation period suspension was 
centrifugated at 1500 G for 5 minutes. MTT (3-(4.5-dimethyl- 
tiazol -2)-2.5- diphenyltetrazolium bromide) the (Sigma) so-
lution was added to sedemented cells (30 microliter for 100 
microlitre suspension; MMT was diluted in buffer) (140 mM 
NaCl, 5mM HEPES, pH 7.4) in dose of 2.5 mg for each MTT 
300 microliter buffer) and incubated for 4 hours at 37°C in 
a 5% CO2 condition. After the incubation we carefully took 
supernatant and added a 100% dimethyl sulfoxide (DMSO) 
dilutant to a 100 microliter.
Absorption was measured at spectrophotometer at a 570 
nm wave-length. Through the research of suspension we de-
termined that the average rate of measurement, divided by 
the average rate of control (separately for soil) calculates the 
coefficient of proliferation through the following formula:
K = Atrial/Acontrol
In cytotoxicity tests using the MTT detection method, 
target cell death was calculated as follows (10):
% of target cell death = (A550 (effectors + targets) – A550 (effectors)/
A 550 (targets) x 100
We determined the rate of absorbance of effector or tar-
get cells as 550 nm (A550) through separate cultures con-
taining either effector or target cells alone.
We conducted statistic processing of the obtained re-
sults according to the SPSS 11.0 program. A student’s t-test 
was used for the analysis of differences between means and 
thechange of the p value < 0.05 was considered to be statisti-
cally significant.
Results and Discussion
In table 1 the research results show the Jurkat cells’ 
viability (MMT test) of both PHA-stimulated Jurkat cells 
alone and intact Jurkat cells incubated with PHA-stimu-
lated Jurkat cells. As it was revealed, the viability of PHA-
stimulated Jurkat cells is decreased statistically significant 
in comparison with viability of deactivated cells; in the case 
of co-incubation of intact Jurcat cells with PHA-stimulated 
Jurkat cells, there viability decreases with the rising ratio of 
activated and deactivated cells [Jurkat]PHAact/[Jurkat]intact.
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Table 1
Jurkat cells viability (MMT test)
24 hour
Area 0.10 ± 0.02 K
Jurkat 0.52 ± 0.06 1
Jurkat+PHA 0,27 ± 0,04 0.41*
Jurkat+PHA [Jurkat]PHAact/[Jurkat]intact = 0,11
(10%/90%)
0.47 ± 0.09 0.88
[Jurkat]PHAact/[Jurkat]intact = 0,25
(20%/80%)
0. 46 ± 0.05 0.86
[Jurkat]PHAact/[Jurkat]intact = 0,43
(30%+70%)
0.41 ± 0.05 0.73*
[Jurkat]PHAact/[Jurkat]intact = 0,67 
(40%+60%)
0.43 ± 0.04 0.79*
[Jurkat]PHAact/[Jurkat]intact = 1
(50%+50%)
0.37 ± 0.06 0.64*
[Jurkat]PHAact/[Jurkat]intact = 1,5 
(60%+40%)
0.39 ± 
0.054
0.69*
* – Statistical significancy according intact Jurkat cells.
Table 2 there shows the data of the influence of Pheno-
vine on the viability of PHA-stimulated and coincubated 
intact + PHA-stimulated Jurkat cells (MMT test results). It 
was revealed, that Phenovine increases the viability of intact 
cells (by 22%) and PHA-stimulated Jurkat cells (by 60%).
In case of coincubation of intact Jurkat cells with PHA-
stimulated Jurkat cells, Phenovine increases the viability 
100%. In contrast, the viability decreases with the rising 
ratio of activated and non-activated cells [Jurkat]PHA/[Jur-
kat]intact.
Table 3 shows the data of the established influence of 
Phenovine on the intensity of apoptosis in the intact Jurkat 
cells mixed with PHA-stimulated Jurkat cells. As shown in 
table 3, prestimulated Jurkat cells induced the death of their 
non-activated counterparts. The percentage of cell death in-
creased with the effector to target ratio. Phenovine prevents 
cell apoptosis by 20%-s.
Table 2
Influence of Phenovine on the viability of PHA-stimulated and coincubated intact+ PHA-stimulated  
Jurkat cells (MMT test results)
Intact Phenovine
I K I K
Area 0.10 ± 0.02
Jurkat 0.524 ± 0.062 1 0.617 ± 0.037 1.22**
Jurkat+PHA 0.273 ± 0.040 0.41* 0.447 ± 0.058
2.01**
 
 0.67***
[Jurkat]PHA/[Jurkat]intact = 3/2 0.394 ± 0.054 0.69* 0.624 ± 0.039 1.78**  1.0
[Jurkat]PHA/[Jurkat]intact = 2/3 0.434 ± 0.044 0,79* 0.657 ± 0.023 1.67** 1,1
* – Statistical significancy according intact Jurkat cells.
** – Statistical significancy between Jurkat cells bioviability with/without Phenovine.
*** – Statistical significancy according intact Jurkat cells + Phenovine.
Table 3
Influence of Phenovine on the intensity of apoptosis intact 
Jurkat cells mixed with of PHA-stimulated Jurkat cells 
(MMT test results)
Intact % Phenovine %
[Jurkat]PHA/[Jurkat]intact = 2/3
(40% + 60%) 60% 40%
[Jurkat]PHA/[Jurkat]intact = 3/2
(60% + 40%) 50% 28%
Conclusion
The viability of Jurkat cells decreases (apoptosis intensity 
increases) with the rising ratio of activated and nonactivated 
cells [Jurkat]PHA/[Jurkat]intact.
P – Phenovin increases the viability of PHA-stimulated 
Jurkat cells and prevents their apoptosis.
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Prognostic scores in the context of severe 2009 AH1N1 influenza pneumonias
In this paper we analyzed the applicability of the classical prognostic scores – PSI, CURB65, CRB65, and ADROP used for evaluating community 
acquired pneumonia in patients during 2009 with AH1N1 influenza complicated with severe pneumonia. The analyzed scores were retrospectively applied 
to a prospective cohort of 75 fatal cases with requirement for invasive mechanical ventilation (IMV). All scores showed a very low sensitivity in scores’ 
classes corresponding to severe pneumonia, when used for prediction of deathfatal cases (PSI > IV – 20%; CURB65 > 3 – 33.3%; CRB65 > 2 – 53.3; 
ADROP > 4 – 6.7%), as well as the need for IMV (PSI > IV – 17.2%; CURB65 > 3 – 44.8%; CRB65 > 2 – 10.3%; ADROP >4 – 3.4%). Thus, we concluded 
by analyzing the scores that the probability of death and the need for IMV was underestimated in patients with severe influenza pneumonia.
Key words: influenza pneumonia, prognostic scores, CUBR65, CRB65, ADROP, PSI.
Прогностические шкалы в контексте гриппозных пневмоний 2009 AH1N1 с тяжелым течением
В представленной работе анализируется применимость классических прогностических шкал (PSI, CURB65, CRB65, ADROP, используемых 
при оценке тяжести внебольничной пневмонии) у пациентов с гриппом 2009 AH1N1 осложненным пневмонией с тяжелым течением. Проана-
лизированные шкалы были ретроспективно применены к проспективно сформированной когорте, состоящей из 75 случаев тяжелых больных, 
2009 AH1N1 гриппозных пневмоний, для оценки вероятности наступления смерти или необходимости применения инвазивной вентиляции 
легких (ИВЛ). Все шкалы показали очень низкую чувствительность, в классах соответствующих тяжелой пневмонии, при использовании для 
оценивания вероятности смерти (PSI > IV – 20%; CURB65 > 3 – 33,3%; CRB65 > 2 – 53,3; ADROP > 4 – 6,7%), или необходимость ИВЛ (PSI > 
IV – 17,2%; CURB65 > 3 – 44,8%; CRB65 > 2 – 10,3%; ADROP > 4 – 3,4%). Полученные результаты доказывают недооценивание проанализиро-
ванными шкалами вероятности смерти и необходимости применения ИВЛ у больных с тяжелой гриппозной пневмонией.
Ключевые слова: гриппозная пневмония, прогностические шкалы, CUBR65, CRB65, ADROP, PSI.
Introducere
Virusul gripal 2009 AH1N1 continuă să fie cel mai frecvent 
subtip viral izolat pe parcursul ultimelor sezoane gripale [1]. 
Posibilitatea evoluţiei nefaste, adesea fulminante, a infecţiei 
gripale 2009 AH1N1, suprapusă afluxului masiv de pacienţi 
în perioadele de epidemie, impune necesitatea aplicării unor 
instrumente prognostice ce ar permite diferenţierea promp-
tă a pacienţilor cu un risc sporit pentru evoluţia nefastă a 
gripei. Deşi scorurile prognostice clasice aplicate în cazul 
pneumoniilor comunitare (PC) au fost elaborate şi validate 
pentru pneumoniile bacteriene, aplicarea acestora pare a fi 
argumentată şi la pacienţii cu pneumonii gripale.
În prezenta lucrare ne-am propus să analizăm aplicabilita-
tea scorurilor prognostice clasice de evaluare a pneumoniilor 
